Last --
Change Today 0.00 / 0.00%
Volume 0.0
4568 On Other Exchanges
Symbol
Exchange
4568 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited is engaged in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis, etc.; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug. The company’s products also include Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. In addition, it markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma. Further, the company develops, manufactures, and sells non-prescription medications, non-medical goods, cosmetics, and food products; medical devices for healthcare professionals, clinics, and hospitals; drinking water; and pharmaceuticals and drugs for animals, as well as researches, develops, manufactures, and sells vaccines. Additionally, it is involved in the manufacture and contract manufacture of as active pharmaceutical ingredients and intermediates, as well as in the provision of insurance and real estate agency services. The company has a strategic collaboration with Coherus BioSciences, Inc. for the development and commercialization of biosimilar candidates; strategic alliance with Sanford-Burnham Medical Research Institute to study novel drug targets in cardiovascular-metabolic diseases; clinical collaboration agreement with Portola Pharmaceuticals, Inc. for Phase III studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban; and a strategic collaboration with Charleston Laboratories, Inc. to develop and commercialize hydrocodone combination products. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co ltd (4568) Key Developments

Daiichi Sankyo and Charleston Laboratories, Inc. Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products

Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc, announced that the parties have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories' novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of Opioid-Induced Nausea and Vomiting (OINV). CL-108 combines 12.5 mg of immediate-release promethazine with 7.5 mg of hydrocodone and 325 mg of acetaminophen. Charleston recently completed a 465-patient phase 3 trial studying the effects of CL-108 as a treatment for moderate to severe acute pain and the reduction of OINV, where CL-108 demonstrated high statistical significance (P<0.01) in both primary endpoints relative to pain reduction and the symptoms of OINV. Under the terms of the agreement, which is pending Hart-Scott-Rodino clearance, Charleston Laboratories will receive $200 million, split evenly between an upfront cash payment and a near-term milestone and up to an additional $450 million in milestone payments connected to the filing and approval of its novel fixed-dose hydrocodone products in the United States.

Daiichi Sankyo Company, Limited Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Provides Dividend Guidance for the Year Ending March 31, 2015; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2015

Daiichi Sankyo Company, Limited announced consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported revenue of JPY 254,449 million against JPY 252,637 million a year ago. Operating profit was JPY 29,430 million against JPY 15,180 million a year ago. Profit before tax was JPY 27,925 million against JPY 17,514 million a year ago. Profit attributable to owners of the company was JPY 19,986 million or JPY 28.34 per diluted share against JPY 15,024 million or JPY 21.31 per diluted share a year ago. Revenue at the Group as a whole increased owing to sales growth and beneficial exchange rates in Europe and other regions. Operating profit increased by JPY 14.2 billion, or 93.9% year on year. This substantial operating profit increase reflected not only an increase in gross profit but also decreases in selling, general and administrative expenses and research and development expenses. In the first three months of the previous fiscal year, loss on business restructuring at Daiichi Sankyo Europe GmbH was recorded under selling, general and administrative expenses. Profit before tax increased by JPY 10.4 billion, or 59.4% year on year. This increase was not as substantial as the operating profit increase owing to a decrease in financial income and an increase in financial expenses. Profit attributable to owners of the company increased by JPY 5.0 billion or 33.0% year on year. This increase was not as substantial as profit before tax increase due to an increase in the amount of income taxes. For the year ending March 31, 2015, the company expects to pay a second quarter dividend of JPY 30.00 per share and a year end dividend of JPY 30.00 per share. For the year ending March 31, 2015, on consolidated basis, the company expects revenue of JPY 920,000 million, operating profit of JPY 120,000 million, profit before tax of JPY 120,000 million and profit attributable to owners of the company of JPY 78,000 million or JPY 110.80 per share.

Daiichi Sankyo Company, Limited, Q1 2015 Earnings Call, Jul 31, 2014

Daiichi Sankyo Company, Limited, Q1 2015 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥1,838.00 JPY +2.50

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $13.50 USD +0.29
BioMerieux €79.80 EUR +0.36
Exelixis Inc $4.14 USD +0.10
Ipsen SA €36.35 EUR +2.67
Vertex Pharmaceuticals Inc $93.57 USD +0.77
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 19.2x
Price/Sales 1.1x
Price/Book 1.3x
Price/Cash Flow 19.3x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.